NR4A1 and breast cancer: Moreover, the combination of endocrine therapy with inhibitors targeting pathways such as Notch, hypoxia-inducible factor (HIF), and integrin/AKT – which maintain CSCs – effectively reduces the self-renewal capacity of hormone receptor-positive BC cells.